Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image: A clinician reviews blood disorder data in a hospital setting, reflecting Johnson & Johnson’s IMAAVY Phase 2/3 results and the growing focus on FcRn-targeted treatment for warm autoimmune hemolytic anemia.
Pharma & Biotech

Johnson & Johnson’s IMAAVY data sharpen the FcRn strategy beyond myasthenia gravis

Find out how Johnson & Johnson’s IMAAVY data could reshape treatment strategy in warm autoimmune hemolytic anemia.

Read More
Representative image of leukemia drug research as Enliven Therapeutics’ ELVN-001 data put chronic myeloid leukemia treatment, Phase 3 trial planning, and targeted oncology therapy under sharper focus.
Pharma & Biotech

Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies

Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.

Read More
Representative image of acromegaly drug development as Camurus’ Oclaiz FDA setback puts rare disease manufacturing risk, long-acting injectable therapies, and U.S. regulatory scrutiny under sharper focus.
Pharma & Biotech

Camurus Oclaiz CRL shows how one manufacturing site can stall a differentiated endocrine therapy

Find out how Camurus’ fresh FDA setback for Oclaiz could delay its U.S. acromegaly launch and reshape rare disease manufacturing risk.

Read More
Representative image: A clinician uses a handheld skin assessment device, reflecting DermaSensor’s CE Mark and the growing role of AI-assisted skin cancer triage in European primary care.
Pharma & Biotech

Could DermaSensor’s NHS study turn AI skin cancer tools into primary care infrastructure?

Find out how DermaSensor’s CE Mark and NHS study could reshape AI-assisted skin cancer assessment across European primary care.

Read More
Representative image of bone health biologics research as GlycoNex’s SPD8 Phase III result puts denosumab biosimilar competition, osteoporosis care, and oncology bone disease treatment under sharper focus.
Pharma & Biotech

GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal

Find out how GlycoNex’s SPD8 Phase III data could intensify denosumab biosimilar competition in osteoporosis and oncology care.

Read More
Representative image of Alzheimer’s disease research as Elixiron’s enrupatinib data put neuroinflammation, brain imaging, and oral drug development under sharper clinical focus.
Pharma & Biotech

Elixiron’s oral Alzheimer’s drug data raise a bigger question: can neuroinflammation become the next serious treatment target?

Find out how Elixiron’s enrupatinib Phase 2 data could reshape Alzheimer’s neuroinflammation research and what risks remain.

Read More
Representative image of a sleep medicine setting as Apnimed’s AD109 oral therapy advances debate over obstructive sleep apnea treatment, Phase 3 data, and potential FDA review.
Pharma & Biotech

Apnimed advances oral OSA therapy case as AD109 heads toward FDA decision window

Find out how Apnimed’s AD109 Phase 3 data could reshape oral treatment for obstructive sleep apnea as FDA review approaches.

Read More
Pharma & Biotech

Optimi Health’s first UK psilocybin export signals bigger test for GMP psychedelic manufacturing

Find out how Optimi Health’s UK psilocybin export could reshape psychedelic trial supply and what risks remain for Phase 2 research.

Read More
Pharma & Biotech

Why Cartesian Therapeutics’ WestGene pact could intensify the race for autoimmune cell therapy

Find out how Cartesian Therapeutics’ WestGene deal could reshape in vivo CAR-T strategy in autoimmune disease and what risks remain.

Read More
Pharma & Biotech

Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test

Find out how FDA alignment on ATH434 could shape Alterity Therapeutics’ pivotal Phase 3 path in multiple system atrophy.

Read More